152 related articles for article (PubMed ID: 9193847)
21. Improved attainment of NKF classified lipid target levels after conversion from cyclosporine to tacrolimus in renal graft recipients.
Pohanka E; Margreiter R; Sparacino V; Sperschneider H;
Transplant Proc; 2005 May; 37(4):1874-6. PubMed ID: 15919490
[TBL] [Abstract][Full Text] [Related]
22. Significance of dyslipidaemia in patients with heart failure of unexplained aetiology.
Skwarek M; Bilińska ZT; Mazurkiewicz Ł; Grzybowski J; Kruk M; Kurjata P; Piotrowski W; Ruzyłło W
Kardiol Pol; 2008 May; 66(5):515-22, discussion 523-4. PubMed ID: 18537059
[TBL] [Abstract][Full Text] [Related]
23. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicentric Study in kidney transplant patients.
Morales JM; Andrés A; Dominguez-Gil B; Arriola M; Gutiérrez MJ; Hernández E; Ortuño T; Praga M
Transplant Proc; 2005 Nov; 37(9):3738-42. PubMed ID: 16386523
[TBL] [Abstract][Full Text] [Related]
24. Long term efficacy of simvastatin in renal transplant recipients treated with cyclosporine or tacrolimus.
Imamura R; Ichimaru N; Moriyama T; Shi Y; Namba Y; Nonomura N; Matsumiya K; Toki K; Takahara S; Okuyama A
Clin Transplant; 2005 Oct; 19(5):616-21. PubMed ID: 16146552
[TBL] [Abstract][Full Text] [Related]
25. Do blood pressure and arterial wall properties change after conversion from cyclosporine to tacrolimus?
Gelens MA; Christiaans MH; v Hooff JP
Transplant Proc; 2005 May; 37(4):1900-1. PubMed ID: 15919498
[TBL] [Abstract][Full Text] [Related]
26. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation.
Wissing KM; Unger P; Ghisdal L; Broeders N; Berkenboom G; Carpentier Y; Abramowicz D
Transplantation; 2006 Sep; 82(6):771-8. PubMed ID: 17006324
[TBL] [Abstract][Full Text] [Related]
27. Impact of changing immunosuppressive monotherapy from Cyclosporin A to Tacrolimus in long-term, stable liver transplant recipients.
Ott R; Bussenius-Kammerer M; Reck T; Koch CA; Kissler H; Hohenberger W; Müller V
Transpl Int; 2004 Jan; 17(1):39-43. PubMed ID: 14504723
[TBL] [Abstract][Full Text] [Related]
28. Impact of fluvastatin on hyperlipidemia after renal transplantation.
Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
[TBL] [Abstract][Full Text] [Related]
29. [Effect of cyclosporin and tacrolimus on lipoprotein oxidation after renal transplantation].
Martínez Castelao A; Ramos R; Serón D; Gil-Vernet S; Fiol C; Gómez-Gerique N; Yzaguirre MT; Hurtado I; Sabaté I; Alsina J; Grinyó JM
Nefrologia; 2002; 22(4):364-9. PubMed ID: 12369128
[TBL] [Abstract][Full Text] [Related]
30. Tacrolimus, cyclosporine and plasma lipoproteins in renal transplant recipients.
Venkiteswaran K; Sgoutas DS; Santanam N; Neylan JF
Transpl Int; 2001 Dec; 14(6):405-10. PubMed ID: 11793038
[TBL] [Abstract][Full Text] [Related]
31. Subclinical inflammation and prothrombotic state in heart transplant recipients: impact of cyclosporin microemulsion vs. tacrolimus.
White M; Ross H; Haddad H; LeBlanc MH; Racine N; Pflugfelder P; Giannetti N; Davies R; Azevedo E; Isaac D; Burton J; Ferguson R; Genest J
Transplantation; 2006 Sep; 82(6):763-70. PubMed ID: 17006323
[TBL] [Abstract][Full Text] [Related]
32. Studies on post-transplant dyslipidemia in kidney transplant patients.
Marubayashi S; Ohdan H; Tashiro H; Tokita D; Onoe T; Hayamizu K; Asahara T; Doi S; Okumoto S; Tanji C; Kawai T; Taniguchi Y; Fukuda Y; Dohi K
Hiroshima J Med Sci; 2005 Jun; 54(2):39-45. PubMed ID: 15991596
[TBL] [Abstract][Full Text] [Related]
33. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
34. Lipid profile in post renal transplant patients treated with cyclosporine in Sudan.
Suleiman B; El Imam M; Elsabigh M; Eltahir K; Eltahir A; Miskeen E
Saudi J Kidney Dis Transpl; 2009 Mar; 20(2):312-7. PubMed ID: 19237829
[TBL] [Abstract][Full Text] [Related]
35. A comparison of the effects of C2-cyclosporine and C0-tacrolimus on renal function and cardiovascular risk factors in kidney transplant recipients.
Kim SJ; Prasad GV; Huang M; Nash MM; Famure O; Park J; Thenganatt MA; Chowdhury N; Cole EH; Fenton SS; Cattran DC; Zaltzman JS; Cardella CJ
Transplantation; 2006 Oct; 82(7):924-30. PubMed ID: 17038908
[TBL] [Abstract][Full Text] [Related]
36. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure.
Waid T;
Clin Transplant; 2005 Oct; 19(5):573-80. PubMed ID: 16146546
[TBL] [Abstract][Full Text] [Related]
37. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation.
Porrini E; Delgado P; Alvarez A; Cobo M; Pérez L; González-Posada JM; Hortal L; Gallego R; García JJ; Checa M; Morales A; Salido E; Hernández D; Torres A
Nephrol Dial Transplant; 2008 Apr; 23(4):1436-41. PubMed ID: 18029372
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial.
Choudhry S; Bagga A; Hari P; Sharma S; Kalaivani M; Dinda A
Am J Kidney Dis; 2009 May; 53(5):760-9. PubMed ID: 19268410
[TBL] [Abstract][Full Text] [Related]
39. [Slowing progression of chronic allograft nephropathy by conversion from cyclosporin A to tacrolimus].
Peng LK; Xie XB; Peng FH; Wang Y; Jiang Y; Lan GB; Fang CH; Nie MH
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb; 32(1):59-62. PubMed ID: 17344588
[TBL] [Abstract][Full Text] [Related]
40. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
